JP2017531028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531028A5 JP2017531028A5 JP2017526774A JP2017526774A JP2017531028A5 JP 2017531028 A5 JP2017531028 A5 JP 2017531028A5 JP 2017526774 A JP2017526774 A JP 2017526774A JP 2017526774 A JP2017526774 A JP 2017526774A JP 2017531028 A5 JP2017531028 A5 JP 2017531028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- cdrs
- cancer
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 65
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 56
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 8
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 8
- 241000282465 Canis Species 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 6
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 description 2
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 2
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- BUJRUSRXHJKUQE-UHFFFAOYSA-N 5-carboxy-X-rhodamine triethylammonium salt Chemical compound CC[NH+](CC)CC.[O-]C(=O)C1=CC(C(=O)[O-])=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 BUJRUSRXHJKUQE-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012104 Alexa Fluor 500 Substances 0.000 description 1
- 239000012105 Alexa Fluor 514 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940122544 PD-1 agonist Drugs 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- -1 hydroxy Tryptamine Chemical compound 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- YEOUFHBJWTZWCZ-UHFFFAOYSA-M sulforhodamine G Chemical compound [Na+].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O YEOUFHBJWTZWCZ-UHFFFAOYSA-M 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033177P | 2014-08-05 | 2014-08-05 | |
| US62/033,177 | 2014-08-05 | ||
| US201462053366P | 2014-09-22 | 2014-09-22 | |
| US62/053,366 | 2014-09-22 | ||
| US201462093368P | 2014-12-17 | 2014-12-17 | |
| US62/093,368 | 2014-12-17 | ||
| PCT/IB2015/055943 WO2016020856A2 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531028A JP2017531028A (ja) | 2017-10-19 |
| JP2017531028A5 true JP2017531028A5 (OSRAM) | 2018-09-20 |
| JP6629321B2 JP6629321B2 (ja) | 2020-01-15 |
Family
ID=53836144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526774A Active JP6629321B2 (ja) | 2014-08-05 | 2015-08-05 | 免疫学的試薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9982053B2 (OSRAM) |
| EP (1) | EP3177644B1 (OSRAM) |
| JP (1) | JP6629321B2 (OSRAM) |
| KR (1) | KR102357893B1 (OSRAM) |
| CN (1) | CN107074947B (OSRAM) |
| AU (1) | AU2015298356B2 (OSRAM) |
| CA (1) | CA2957258C (OSRAM) |
| DK (1) | DK3177644T3 (OSRAM) |
| ES (1) | ES2847311T3 (OSRAM) |
| PL (1) | PL3177644T3 (OSRAM) |
| PT (1) | PT3177644T (OSRAM) |
| SG (1) | SG11201700672YA (OSRAM) |
| WO (1) | WO2016020856A2 (OSRAM) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| CA2957258C (en) * | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| CN116333138A (zh) | 2015-07-30 | 2023-06-27 | 宏观基因有限公司 | Pd-1结合分子和其使用方法 |
| AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| CA3012075A1 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| IL263542B2 (en) * | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| TWI781120B (zh) * | 2016-11-02 | 2022-10-21 | 美商永斯醫療股份有限公司 | Ｐｄ-１之抗體及其用途 |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2018127710A1 (en) * | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| BR112019014510A2 (pt) | 2017-01-13 | 2020-02-18 | Agenus Inc. | Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| US11161905B2 (en) | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| TW202402800A (zh) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| MX2019014577A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
| WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF |
| JP2020532991A (ja) | 2017-09-07 | 2020-11-19 | オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド | プログラム細胞死タンパク質１に対する抗体 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| CN111683968B (zh) | 2017-11-13 | 2024-07-05 | 克雷森多生物制剂有限公司 | 结合至cd137和psma的分子 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| CN119899267A (zh) * | 2018-03-22 | 2025-04-29 | 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 | 拮抗性pd-1、pd-l1和lag-3结合蛋白 |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CA3104467A1 (en) | 2018-06-20 | 2019-12-26 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
| KR20220008253A (ko) | 2019-01-03 | 2022-01-20 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| US12344850B2 (en) | 2019-07-30 | 2025-07-01 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| KR102231974B1 (ko) * | 2019-08-23 | 2021-03-25 | 한국과학기술원 | 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| PH12022550460A1 (en) | 2019-08-30 | 2023-02-27 | Agenus Inc | Anti-cd96 antibodies and methods of use thereof |
| AU2020369599A1 (en) | 2019-10-23 | 2022-05-12 | Monsanto Technology Llc | Compositions and methods for RNA-templated editing in plants |
| KR20220110739A (ko) | 2019-10-30 | 2022-08-09 | 페어와이즈 플랜츠 서비시즈, 인크. | 유형 v crispr-cas 염기 편집제 및 그의 사용 방법 |
| IL292434A (en) | 2019-11-05 | 2022-06-01 | Pairwise Plants Services Inc | Compositions and methods for rna-encoded dna-replacement of alleles |
| CN114787181A (zh) | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法 |
| WO2021113788A1 (en) | 2019-12-06 | 2021-06-10 | Pairwise Plants Services, Inc. | Recruitment methods and compounds, compositions and systems for recruitment |
| US20210238598A1 (en) | 2020-01-30 | 2021-08-05 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| CA3165291A1 (en) | 2020-01-31 | 2021-08-05 | Pairwise Plants Services, Inc. | Suppression of shade avoidance response in plants |
| WO2021158798A1 (en) | 2020-02-04 | 2021-08-12 | Pairwise Plants Services, Inc. | Thornless / prickleless rubus plants |
| WO2021168288A1 (en) | 2020-02-21 | 2021-08-26 | Pairwise Plants Services, Inc. | Improved resistance to soybean cyst nematode through gene editing |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11999946B2 (en) | 2020-03-26 | 2024-06-04 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| US11882808B2 (en) | 2020-03-27 | 2024-01-30 | Pairwise Plants Services, Inc. | Methods for improving resistance to soybean rust |
| US20230175006A1 (en) | 2020-04-06 | 2023-06-08 | Pairwise Plants Services, Inc. | Methods and compositions for increasing resistance to ear rot and stem rot disease in maize |
| MX2022012878A (es) | 2020-04-16 | 2022-12-08 | Pairwise Plants Services Inc | Metodos para controlar el tama?o del meristema para la mejora de cultivos. |
| BR112022022352A2 (pt) * | 2020-05-04 | 2023-01-10 | Inhibrx Inc | Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| LT4157876T (lt) | 2020-05-26 | 2024-10-25 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antikūnai |
| BR112022024489A2 (pt) | 2020-06-02 | 2023-01-31 | Pairwise Plants Services Inc | Métodos para o controle do tamanho do meristema para melhora da cultura agrícola |
| CN115943212A (zh) | 2020-06-17 | 2023-04-07 | 成对植物服务股份有限公司 | 控制分生组织大小以改良作物的方法 |
| EP4172328A1 (en) | 2020-06-30 | 2023-05-03 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| EP4204436A1 (en) | 2020-08-28 | 2023-07-05 | Pairwise Plants Services, Inc. | Engineered crispr-cas proteins and methods of use thereof |
| US20220145334A1 (en) | 2020-11-06 | 2022-05-12 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| BR112023015909A2 (pt) | 2021-02-11 | 2023-11-21 | Monsanto Technology Llc | Métodos e composições para modificar níveis de citocinina oxidase em plantas |
| WO2022182834A1 (en) | 2021-02-25 | 2022-09-01 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture in plants |
| CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| WO2022265905A2 (en) | 2021-06-14 | 2022-12-22 | Pairwise Plants Services, Inc. | Reporter constructs, compositions comprising the same, and methods of use thereof |
| CA3223995A1 (en) | 2021-06-17 | 2022-12-22 | Pairwise Plants Services, Inc. | Modification of growth regulating factor family transcription factors in soybean |
| UY39827A (es) | 2021-06-24 | 2023-01-31 | Pairwise Plants Services Inc | Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento |
| EP4362663A1 (en) | 2021-07-01 | 2024-05-08 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing root system development |
| CN113702351B (zh) * | 2021-07-14 | 2024-08-20 | 吉林大学 | 一种对天然药物产物进行筛选和垂钓的方法 |
| EP4384626A1 (en) | 2021-08-12 | 2024-06-19 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| UY39902A (es) | 2021-08-17 | 2023-03-31 | Pairwise Plants Services Inc | Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant |
| CN118265446A (zh) | 2021-08-30 | 2024-06-28 | 成对植物服务股份有限公司 | 修饰植物中的泛素结合肽酶基因以改善产量性状 |
| AR126938A1 (es) | 2021-09-02 | 2023-11-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento |
| US20230087522A1 (en) | 2021-09-21 | 2023-03-23 | Pairwise Plants Services, Inc. | Methods and compositions for reducing pod shatter in canola |
| WO2023049728A1 (en) | 2021-09-21 | 2023-03-30 | Pairwise Plants Services, Inc. | Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same |
| WO2023060028A1 (en) | 2021-10-04 | 2023-04-13 | Pairwise Plants Services, Inc. | Methods for improving floret fertility and seed yield |
| WO2023060152A2 (en) | 2021-10-07 | 2023-04-13 | Pairwise Plants Services, Inc. | Methods for improving floret fertility and seed yield |
| UY40060A (es) | 2021-12-09 | 2023-07-14 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas |
| US20230295646A1 (en) | 2021-12-13 | 2023-09-21 | Pairwise Plants Services, Inc. | Model editing systems and methods relating to the same |
| GB2629276A (en) | 2022-01-06 | 2024-10-23 | Pairwise Plants Services Inc | Methods and compositions for trichome removal |
| WO2023147470A2 (en) | 2022-01-28 | 2023-08-03 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| AR128372A1 (es) | 2022-01-31 | 2024-04-24 | Pairwise Plants Services Inc | Supresión de la respuesta de evitación de la sombra en las plantas |
| CA3253290A1 (en) | 2022-02-28 | 2023-08-31 | Pairwise Plants Services Inc | MODIFIED CRISPR-CAS EFFECTOR PROTEINS AND THEIR METHODS OF USE |
| MX2024010647A (es) | 2022-03-02 | 2024-09-06 | Pairwise Plants Services Inc | Modificacion de genes del receptor de brasinoesteroides para mejorar rasgos de rendimiento. |
| CN115015536A (zh) * | 2022-03-30 | 2022-09-06 | 邹灵龙 | 一种即时检测pd-1抗体药浓度的试纸条和试剂盒 |
| PE20250266A1 (es) | 2022-03-31 | 2025-01-29 | Pairwise Plants Services Inc | Plantas rosaceae de floracion temprana con caracteristicas mejoradas |
| CN119301147A (zh) | 2022-04-07 | 2025-01-10 | 成对植物服务股份有限公司 | 提高对镰孢菌头枯病的抗性的方法和组合物 |
| EP4511387A1 (en) | 2022-04-21 | 2025-02-26 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| WO2023215704A1 (en) | 2022-05-02 | 2023-11-09 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing yield and disease resistance |
| US20230416767A1 (en) | 2022-05-05 | 2023-12-28 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture and/or improving plant yield traits |
| UY40326A (es) | 2022-06-27 | 2023-12-29 | Pairwise Plants Services Inc | Métodos y composiciones para modificar el escape a la sombra en plantas |
| US20240000031A1 (en) | 2022-06-29 | 2024-01-04 | Pairwise Plants Services, Inc. | Methods and compositions for controlling meristem size for crop improvement |
| WO2024006792A1 (en) | 2022-06-29 | 2024-01-04 | Pairwise Plants Services, Inc. | Methods and compositions for controlling meristem size for crop improvement |
| UY40384A (es) | 2022-08-04 | 2024-02-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar rasgos de rendimiento |
| CN119654065A (zh) | 2022-08-11 | 2025-03-18 | 成对植物服务股份有限公司 | 用于控制分生组织大小以进行作物改良的方法和组合物 |
| UY40418A (es) | 2022-09-08 | 2024-04-02 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar características de rendimiento en plantas |
| WO2024130102A2 (en) | 2022-12-16 | 2024-06-20 | Pairwise Plants Services, Inc. | Fusion proteins comprising an intein polypeptide and methods of use thereof |
| WO2024137911A1 (en) | 2022-12-21 | 2024-06-27 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| US20240279673A1 (en) | 2023-02-16 | 2024-08-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying shade avoidance in plants |
| WO2024182746A1 (en) | 2023-03-01 | 2024-09-06 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| AR132019A1 (es) | 2023-03-02 | 2025-05-21 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la evitación de la sombra en plantas |
| AR132071A1 (es) | 2023-03-09 | 2025-05-21 | Pairwise Plants Services Inc | Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas |
| US20240324536A1 (en) | 2023-03-30 | 2024-10-03 | Pairwise Plants Services, Inc. | Methods and compositions for reducing thorns or prickles in plants |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| AU2024269008A1 (en) | 2023-05-10 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| UY40746A (es) | 2023-05-18 | 2024-12-13 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar las características de rendimiento de las plantas |
| AR133164A1 (es) | 2023-07-18 | 2025-09-03 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectura radicular en plantas |
| AR133310A1 (es) | 2023-07-27 | 2025-09-17 | Pairwise Plants Services Inc | Métodos y composiciones para modificar rasgos de rendimiento de las plantas |
| WO2025064734A1 (en) | 2023-09-21 | 2025-03-27 | Pairwise Plants Services, Inc. | Early flowering black raspberry plants with improved characteristics |
| WO2025072430A1 (en) | 2023-09-26 | 2025-04-03 | Pairwise Plants Services, Inc. | Crispr-cas fusion proteins with adenine base editor functionality, compositions comprising the same, and methods of use thereof |
| US20250129348A1 (en) | 2023-10-09 | 2025-04-24 | Pairwise Plants Services, Inc. | Circular permutants, compositions comprising the same, and methods of use thereof |
| WO2025080600A1 (en) | 2023-10-11 | 2025-04-17 | Pairwise Plants Services, Inc. | Methods and compositions for improving crop yield traits |
| WO2025137408A1 (en) | 2023-12-21 | 2025-06-26 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| WO2025178902A1 (en) | 2024-02-22 | 2025-08-28 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE132195T1 (de) | 1987-03-02 | 1996-01-15 | Whitehead Biomedical Inst | Rekombinant-mykobakterielle impfstoffe |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| CA2076753A1 (en) | 1990-02-26 | 1991-08-27 | Anthony J. Radford | Shuttle plasmid for escherichia coli and mycobacteria |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992021376A1 (en) | 1991-06-06 | 1992-12-10 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| WO1994028933A1 (en) | 1993-06-04 | 1994-12-22 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP2290107A1 (en) | 2003-01-07 | 2011-03-02 | Dyax Corporation | Kunitz domain library |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| NZ720288A (en) | 2006-12-27 | 2020-02-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342228B1 (en) * | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| WO2011100841A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| EP2545078A1 (en) * | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| AR087405A1 (es) * | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013126809A1 (en) * | 2012-02-23 | 2013-08-29 | Sloan-Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| AU2013327116C1 (en) * | 2012-10-02 | 2018-08-30 | Bristol-Myers Squibb Company | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| ES2792183T3 (es) * | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| CA2957258C (en) * | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| CA3012075A1 (en) * | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
-
2015
- 2015-08-05 CA CA2957258A patent/CA2957258C/en active Active
- 2015-08-05 ES ES15750136T patent/ES2847311T3/es active Active
- 2015-08-05 CN CN201580042199.7A patent/CN107074947B/zh active Active
- 2015-08-05 US US15/329,760 patent/US9982053B2/en active Active
- 2015-08-05 PL PL15750136T patent/PL3177644T3/pl unknown
- 2015-08-05 PT PT157501362T patent/PT3177644T/pt unknown
- 2015-08-05 WO PCT/IB2015/055943 patent/WO2016020856A2/en not_active Ceased
- 2015-08-05 SG SG11201700672YA patent/SG11201700672YA/en unknown
- 2015-08-05 EP EP15750136.2A patent/EP3177644B1/en active Active
- 2015-08-05 KR KR1020177004575A patent/KR102357893B1/ko active Active
- 2015-08-05 AU AU2015298356A patent/AU2015298356B2/en active Active
- 2015-08-05 DK DK15750136.2T patent/DK3177644T3/da active
- 2015-08-05 JP JP2017526774A patent/JP6629321B2/ja active Active
-
2018
- 2018-05-17 US US15/981,977 patent/US11130807B2/en active Active
-
2021
- 2021-09-27 US US17/485,752 patent/US20220169733A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531028A5 (OSRAM) | ||
| RU2008146922A (ru) | Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) | |
| JP2018532766A5 (OSRAM) | ||
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2017519759A5 (OSRAM) | ||
| JP2020097579A (ja) | 毒性部分を備える異常細胞拘束性免疫グロブリン | |
| JP2013506428A5 (OSRAM) | ||
| JP2019500020A5 (OSRAM) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| JP2016503295A5 (OSRAM) | ||
| JP2020515247A5 (OSRAM) | ||
| JP2007526880A5 (OSRAM) | ||
| BR112013001640A2 (pt) | anticorpo monoclonal que se liga aos epítopos de epha2 e cd44, seu uso no tratamento de câncer e na detecção de célula cancerosa, bem como composição, kit, ácido nucleico e vetor 5 de expressão | |
| JP2015519375A5 (OSRAM) | ||
| JP2020534012A5 (OSRAM) | ||
| JP2020500834A5 (OSRAM) | ||
| Aria et al. | Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: a systematic review | |
| JP2020515277A5 (OSRAM) | ||
| WO2023131193A1 (zh) | 靶向人b7-h3分子的人源化单克隆抗体及其应用 | |
| JP7711208B2 (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| JP2019509046A5 (OSRAM) | ||
| CN119948063A (zh) | 结合egfr和b7-h3的双特异性抗体 | |
| KR101828794B1 (ko) | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체 | |
| US20230365676A1 (en) | Cd33 antibodies | |
| WO2017093985A4 (en) | Hiv binding agents |